SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-001379
Filing Date
2022-01-18
Accepted
2022-01-18 06:07:15
Documents
15
Period of Report
2022-01-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 59570
2 ex10-7.htm EX-10.7 25388
3 ex10-7_001.jpg GRAPHIC 12754
  Complete submission text file 0001493152-22-001379.txt   330017

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ensc-20220118.xsd EX-101.SCH 3778
5 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ensc-20220118_def.xml EX-101.DEF 26881
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ensc-20220118_lab.xml EX-101.LAB 36943
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ensc-20220118_pre.xml EX-101.PRE 25503
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5593
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 22533466
SIC: 2834 Pharmaceutical Preparations